f/tPSA比值在前列腺增生与前列腺癌的诊断价值

目的:探讨血清中的前列腺特异性抗原(tPSA)、游离PSA(fPSA)及f/tPSA对前列腺增生(BHP)与前列腺癌(PCA)的诊断价值。方法:采用免疫荧光法检测经病理诊断60例前列腺增生和20例前列腺癌患者血清中的特异性抗原、游离PSA,并计算f/tPSA比值。结果:血清PSA在4 ng/ml～10 ng/ml时,前列腺增生与前列腺癌组的特异性抗原含量差异无显著性(P0.05),游离PSA、f/tPSA比值差异具有显著性(P0.05)。结论:在前列腺增生和前列腺癌诊断灰区,tPSA作为筛选前列腺癌的临界值存在一定缺陷;联合测定tPSA、fPSAP、f/tPSA可明显提高对PCA诊断的特异性,特别是当tPSA为4.0～10.0μg/L诊断灰区时,f/t比值对诊断前列腺癌有重要的临床意义。

Diagnosis significance of relative value of f/tPSA for prostate cancer and bisectional prostate hypertrophy

Objective： It is to investigate the diagnosis significance of total prostate specific antigen（tPSA）,free prostate specific antigen（fPSA）and f/tPSA for prostate cancer（PCA） and bisectional prostate hypertrophy（BHP） Methods： 20patients with PCa and 60 patients with benign prostatic hypertrophy（BPH） were diagnosed by pathobiology whose levelsof tPSA,andfPSA were examined in serums by Immunofluorecence assay（FIA）.The results were analyzed.Results：When tPSA level isfrom 4.0-10.0μg/L in gray zone,The difference in serum tPSA between the twogroups was not significant（P0.05）,but f/t of Pca group was significantly lower than that of BPHgroup（P0.05）.Conclusion： benign prostatic hypertrophy and prostate cancer were in gray zone.It is unreasonable that tPSA is regarded as a critical value for the diagnosis of prostate carcinoma.When tPSA level is from 4.0-10.0μg/L in gray zone,f/ t ratio has a significant value for diagnosing PCA.